Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oral Tenapanor in Breast Milk
NCT06203444Phase 1Completed
- Sponsor
- Ardelyx
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenapanor in irritable bowel syndrome (IBS), sponsored by Ardelyx. Primary endpoint: Concentration of tenapanor and its major metabolite in breast milk. Started Nov 2023; status: completed.
02
Drugs
tenapanor
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06203444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203444.